세계의 분자진단 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 검사 부위별, 기술별, 용도별, 지역별, 부문 예측(2025-2030년)

Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Test Location (Point of Care, Self-Test), By Technology, By Application, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

분자진단 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 분자진단 시장 규모는 2030년까지 330억 8,000만 달러에 이르며, 2025년부터 2030년까지의 CAGR은 3.97%로 확대될 것으로 추정됩니다.

시장 축소는 COVID-19의 분자 검사 수요 감소로 인한 것입니다.

분자진단은 효과적이고 신속한 결과를 얻을 수 있기 때문에 전염병 검사에서 중요한 역할을 수행합니다. 유전성 질환에 대한 이환율과 인지도 증가는 시장 성장을 더욱 가속화할 것으로 예측됩니다. 바이오테크놀로지, 바이오칩, 마이크로플루이딕스의 3가지 기본 분자 분석의 소형화는 진단 결과의 정확도와 특이성을 향상시키고 분자진단 제품 수요가 증가할 것으로 예상됩니다. 빠르고 효과적인 검사 결과를 얻을 수 있는 PoC 분자진단 검사의 가용성이 높아질 것으로 예상됩니다.

기업은 중소기업 인수로 제품 포트폴리오를 확대하고 있습니다. 달러로 인수하는 것을 발표했습니다. Hoffmann-La Roche Ltd.는 GenMark Diagnostics, Inc.를 주당 24.05달러의 현금으로 인수하고 GenMark Diagnostics, Inc.의 총 주식 수의 약 82.89%를 보유하고 있습니다. XT-8이나 ePlex와 같은 독자 기술을 가지고 있어 혈류 감염증을 포함한 감염증 검사의 개발에 활용할 수 있습니다.

기타 활동으로는 신흥 질환을 목표로 한 키트 개발을위한 연구 개발 활동을 강화하거나 다른 키트 제조 회사와 계약을 체결하여 실시간 PCR 장비 검사 옵션의 폭을 넓히고 있습니다. 이것은 Roche Diagnostics의 Cobas 4800의 Cobas HPV 테스트 분석의 채용이 포함됩니다. Cepheid에 의한 GeneXpert 플랫폼에서의 결핵 검사 Xpert 분석의 채용도 이러한 진보의 예입니다.

분자진단 시장 보고서 하이라이트

• 시약 부문이 시장을 독점하여 2024년 세계 매출의 65.44%를 차지했습니다. 됩니다.
• 폴리머 라제 연쇄반응 기술 부문은 2024 년에 가장 큰 수익 공유를 차지했습니다.
• 감염증 분야는 2024년에 최대의 수익 점유율을 차지했습니다.
• 중앙검사실에 있어서의 COVID 검사나 기타 헬스케어 적응증의 검사 건수가 많기 때문에 중앙 검사실 부문이 2024년에 업계를 지배했습니다.
• 북미가 시장을 독점했으며 2024년 점유율은 40.95%였습니다. 을 밀어주고 있기 때문입니다.
• 아시아태평양은 시장 침투가 진행되고 있음, 신규 진단 기술 채택 확대를 위한 현지 시장 기업의 이니셔티브, 미충족 시장 요구가 높기 때문에 2025년부터 2030년에 걸쳐 큰 성장을 보일 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 분자진단의 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 분자진단 분석 도구
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 분자진단 시장 : 부문 분석, 제품별, 2018-2030년(백만 달러)

• 정의와 범위
• 제품 시장 점유율 분석, 2024년·2030년
• 분자진단 시장, 제품별, 2018-2030년
• 시장 규모와 예측과 동향 분석, 2018-2030년

제5장 분자진단시장 : 부문 분석, 검사부위별, 2018-2030년(백만 달러)

• 정의와 범위
• 검사 부위 시장 점유율 분석, 2024년·2030년
• 세계의 분자진단 시장, 검사 부위별, 2018-2030년
• 시장 규모와 예측과 동향 분석, 2018-2030년

제6장 분자진단 시장 : 부문 분석, 기술별, 2018-2030년(백만 달러)

• 정의와 범위
• 기술 시장 점유율 분석, 2024년·2030년
• 세계의 분자진단 시장, 기술별, 2018-2030년
• 시장 규모와 예측과 동향 분석, 2018-2030년

제7장 분자진단 시장 : 부문 분석, 용도별, 2018-2030년(백만 달러)

• 정의와 범위
• 용도 시장 점유율 분석, 2024년·2030년
• 세계의 분자진단 시장, 용도별, 2018-2030년
• 시장 규모와 예측과 동향 분석, 2018-2030년

제8장 분자진단시장 : 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년:
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 스페인
  • 이탈리아
  • 벨기에
  • 스위스
  • 네덜란드
  • 폴란드
  • 오스트리아
  • 덴마크
  • 스웨덴
  • 터키
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 태국
  • 스리랑카
  • 말레이시아
  • 베트남
  • 싱가포르
• 라틴아메리카
  • 브라질
  • 콜롬비아
  • 칠레
  • 페루
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 요르단
  • 아랍에미리트(UAE)
  • 카타르
  • 이집트
  • 쿠웨이트

제9장 경쟁 구도

• 시장 진출기업의 분류
• 최근의 동향과 영향 분석, 주요 시장 진출기업별
• 기업의 시장 점유율 분석, 2024년
• 주요 기업 프로파일
  • BD
  • BIOMERIEUX
  • Bio-Rad Laboratories, Inc.
  • Abbott
  • Agilent Technologies, Inc.
  • Danaher
  • Hologic Inc.(Gen Probe)
  • Illumina, Inc.
  • Grifols
  • QIAGEN
  • F. Hoffmann-La Roche, Ltd.
  • Siemens Healthineers AG
  • Sysmex Corporatio

JHS

영문 목차

영문목차

Molecular Diagnostics Market Growth & Trends:

The global molecular diagnostics market size is estimated to reach USD 33.08 billion by 2030, expanding at a CAGR of 3.97% from 2025 to 2030, according to a new report by Grand View Research, Inc. The contraction in the market will be due to the decline in demand for molecular testing for COVID-19. However, factors such as the rising geriatric population and increasing demand for technologies such as NGS is expected to drive market growth.

Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results. Hence, the increasing prevalence of hospital-acquired infections & infectious diseases is projected to drive the market over the forecast period. Increasing incidence and awareness regarding genetic disorders is further anticipated to accelerate market growth. The miniaturization of three basic molecular assays-nanobiotechnology, biochips, and microfluidics are expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.

Companies are expanding their product portfolios with the acquisition of smaller companies. For instance, in March 2021, Hologic announced the acquisition of Diagenode-a molecular diagnostic company with a wide range of PCR instruments, facilitating the detection of over 30 bacteria-for USD 159 million. Similarly, in April 2021, F. Hoffmann-La Roche Ltd. acquired GenMark Diagnostics, Inc. at a price of USD 24.05 per share in cash, and it holds around 82.89% of total shares of GenMark Diagnostics. GenMark Diagnostics, Inc. has proprietary technologies, such as eSensor XT-8 and ePlex, which can be utilized in developing tests for infectious diseases, including bloodstream infections.

Key players are enhancing their range of testing options for real-time PCR instruments by increasing R&D activities for the development of kits that target emerging diseases or by entering into agreements with other kit manufacturing companies. These include the introduction of Cobas HPV test assay in Cobas 4800 by Roche Diagnostics. The introduction of tuberculosis testing Xpert assay on GeneXpert platform by Cepheid is an example of such advancement. Such advances are anticipated to drive the global molecular diagnostics market.

Molecular Diagnostics Market Report Highlights:

• The reagents segment dominated the market and accounted for a share of 65.44% of the global revenue in 2024. It is expected to maintain its dominance throughout the forecast years owing to its wide application scope in research & clinical settings and increasing adoption of novel tests.
• The polymerase chain reaction technology segment accounted for the largest revenue share in 2024. This is attributed to its use in detecting COVID-19 and other infectious diseases.
• The infectious diseases segment accounted for the largest revenue share in 2024. The increased usage of molecular, particularly PCR tests, for diagnosing COVID-19 has increased the segment share significantly.
• The central laboratories segment dominated the industry in 2024 owing to high procedure volumes for COVID testing and other healthcare indications in central laboratories.
• North America dominated the market and accounted for a 40.95% share in 2024. This is attributed to the rising epidemiology of infectious as well as chronic diseases, thus, encouraging companies to introduce novel molecular diagnostic tests, thereby boosting market growth.
• Asia Pacific is anticipated to exhibit significant growth from 2025 to 2030 owing to increased market penetration, initiatives of local market players to increase the adoption of novel diagnostic technologies, and high unmet market needs.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. End Use
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Molecular Diagnostics Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increase in geriatric population
    • 3.2.1.2. Introduction of technologically advanced products
    • 3.2.1.3. Increase in demand for point-of-care Testing
    • 3.2.1.4. Growing prevalence of target diseases
    • 3.2.1.5. Increasing external funding for R&D
    • 3.2.1.6. Outbreak of COVID-19
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Presence of ambiguous regulatory framework
    • 3.2.2.2. High prices of molecular diagnostics tests
• 3.3. Molecular Diagnostics Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Molecular Diagnostics Market: Segment Analysis, By Product, 2018 - 2030 (USD Million)

• 4.1. Definition and Scope
• 4.2. Product Market Share Analysis, 2024 & 2030
• 4.3. Molecular Diagnostics Market, by Product, 2018 to 2030
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 4.4.1. Instruments
    • 4.4.1.1. Instruments market, 2018 - 2030 (USD Million)
  • 4.4.2. Reagents
    • 4.4.2.1. Reagents market, 2018 - 2030 (USD Million)
  • 4.4.3. Others
    • 4.4.3.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Molecular Diagnostics Market: Segment Analysis, By Test Location, 2018 - 2030 (USD Million)

• 5.1. Definition and Scope
• 5.2. Test Location Market Share Analysis, 2024 & 2030
• 5.3. Global Molecular Diagnostics Market, by Test Location, 2018 to 2030
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 5.4.1. Point of care
    • 5.4.1.1. Point of care market, 2018 - 2030 (USD Million)
  • 5.4.2. Self test or OTC
    • 5.4.2.1. Self test or OTC market, 2018 - 2030 (USD Million)
  • 5.4.3. Central laboratories
    • 5.4.3.1. Central laboratories market, 2018 - 2030 (USD Million)

Chapter 6. Molecular Diagnostics Market: Segment Analysis, By Technology, 2018 - 2030 (USD Million)

• 6.1. Definition and Scope
• 6.2. Technology Market Share Analysis, 2024 & 2030
• 6.3. Global Molecular Diagnostics Market, by Technology, 2018 to 2030
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 6.4.1. PCR
    • 6.4.1.1. PCR market, 2018 - 2030 (USD Million)
    • 6.4.1.2. By procedure
      • 6.4.1.2.1. Nucleic acid extraction
        • 6.4.1.2.1.1. Nucleic acid extraction market, 2018 - 2030 (USD Million)
      • 6.4.1.2.2. Others
        • 6.4.1.2.2.1. Others market, 2018 - 2030 (USD Million)
    • 6.4.1.3. By type
      • 6.4.1.3.1. Multiplex
        • 6.4.1.3.1.1. Multiplex market, 2018 - 2030 (USD Million)
      • 6.4.1.3.2. Others
        • 6.4.1.3.2.1. Others market, 2018 - 2030 (USD Million)
    • 6.4.1.4. By product
      • 6.4.1.4.1. Instruments
        • 6.4.1.4.1.1. Instruments market, 2018 - 2030 (USD Million)
      • 6.4.1.4.2. Reagents
        • 6.4.1.4.2.1. Reagents market, 2018 - 2030 (USD Million)
      • 6.4.1.4.3. Others
        • 6.4.1.4.3.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.2. ISH
    • 6.4.2.1. ISH market, 2018 - 2030 (USD Million)
    • 6.4.2.2. Instruments
      • 6.4.2.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.2.3. Reagents
      • 6.4.2.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.2.4. Others
      • 6.4.2.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.3. INAAT
    • 6.4.3.1. INAAT market, 2018 - 2030 (USD Million)
    • 6.4.3.2. Instruments
      • 6.4.3.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.3.3. Reagents
      • 6.4.3.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.3.4. Others
      • 6.4.3.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.4. Chips and microarrays
    • 6.4.4.1. Chips and microarrays market, 2018 - 2030 (USD Million)
    • 6.4.4.2. Instruments
      • 6.4.4.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.4.3. Reagents
      • 6.4.4.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.4.4. Others
      • 6.4.4.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.5. Mass spectrometry
    • 6.4.5.1. Mass spectrometry market, 2018 - 2030 (USD Million)
    • 6.4.5.2. Instruments
      • 6.4.5.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.5.3. Reagents
      • 6.4.5.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.5.4. Others
      • 6.4.5.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.6. Sequencing
    • 6.4.6.1. Sequencing market, 2018 - 2030 (USD Million)
    • 6.4.6.2. Instruments
      • 6.4.6.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.6.3. Reagents
      • 6.4.6.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.6.4. Others
      • 6.4.6.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.7. TMA
    • 6.4.7.1. TMA market, 2018 - 2030 (USD Million)
    • 6.4.7.2. Instruments
      • 6.4.7.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.7.3. Reagents
      • 6.4.7.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.7.4. Others
      • 6.4.7.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.8. Others
    • 6.4.8.1. Others market, 2018 - 2030 (USD Million)
    • 6.4.8.2. Instruments
      • 6.4.8.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.8.3. Reagents
      • 6.4.8.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.8.4. Others
      • 6.4.8.4.1. Others market, 2018 - 2030 (USD Million)

Chapter 7. Molecular Diagnostics Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

• 7.1. Definition and Scope
• 7.2. Application Market Share Analysis, 2024 & 2030
• 7.3. Global Molecular Diagnostics Market, by Application,2018 to 2030
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 7.4.1. Oncology
    • 7.4.1.1. Oncology market, 2018 - 2030 (USD Million)
    • 7.4.1.2. Breast cancer
      • 7.4.1.2.1. Breast cancer market, 2018 - 2030 (USD Million)
    • 7.4.1.3. Prostate cancer
      • 7.4.1.3.1. Prostate cancer market, 2018 - 2030 (USD Million)
    • 7.4.1.4. Colorectal cancer
      • 7.4.1.4.1. Colorectal cancer market, 2018 - 2030 (USD Million)
    • 7.4.1.5. Cervical
      • 7.4.1.5.1. Cervical market, 2018 - 2030 (USD Million)
    • 7.4.1.6. Kidney
      • 7.4.1.6.1. Kidney market, 2018 - 2030 (USD Million)
    • 7.4.1.7. Liver
      • 7.4.1.7.1. Liver market, 2018 - 2030 (USD Million)
    • 7.4.1.8. Blood
      • 7.4.1.8.1. Blood market, 2018 - 2030 (USD Million)
    • 7.4.1.9. Lung
      • 7.4.1.9.1. Lung market, 2018 - 2030 (USD Million)
    • 7.4.1.10. Other
      • 7.4.1.10.1. Other market, 2018 - 2030 (USD Million)
  • 7.4.2. Pharmacogenomics
    • 7.4.2.1. Pharmacogenomics market, 2018 - 2030 (USD Million)
  • 7.4.3. Infectious disease
    • 7.4.3.1. Infectious disease market, 2018 - 2030 (USD Million)
    • 7.4.3.2. MRSA
      • 7.4.3.2.1. MRSA market, 2018 - 2030 (USD Million)
    • 7.4.3.3. Clostridium difficile
      • 7.4.3.3.1. Clostridium difficile market, 2018 - 2030 (USD Million)
    • 7.4.3.4. Vancomycin-resistant enterococci
      • 7.4.3.4.1. Vancomycin-resistant enterococci market, 2018 - 2030 (USD Million)
    • 7.4.3.5. Carbapenem-resistant bacteria testing
      • 7.4.3.5.1. Carbapenem-resistant bacteria testing market, 2018 - 2030 (USD Million)
    • 7.4.3.6. Flu
      • 7.4.3.6.1. Flu market, 2018 - 2030 (USD Million)
    • 7.4.3.7. Respiratory syncytial virus (RSV)
      • 7.4.3.7.1. Respiratory syncytial virus (RSV) market, 2018 - 2030 (USD Million)
    • 7.4.3.8. Candida
      • 7.4.3.8.1. Candida market, 2018 - 2030 (USD Million)
    • 7.4.3.9. Tuberculosis and drug-resistant TB
      • 7.4.3.9.1. Tuberculosis and drug-resistant TB market, 2018 - 2030 (USD Million)
    • 7.4.3.10. Meningitis
      • 7.4.3.10.1. Meningitis market, 2018 - 2030 (USD Million)
    • 7.4.3.11. Gastro-intestinal panel testing
      • 7.4.3.11.1. Gastro-intestinal panel testing market, 2018 - 2030 (USD Million)
    • 7.4.3.12. Chlamydia
      • 7.4.3.12.1. Chlamydia market, 2018 - 2030 (USD Million)
    • 7.4.3.13. Gonorrhea
      • 7.4.3.13.1. Gonorrhea market, 2018 - 2030 (USD Million)
    • 7.4.3.14. HIV
      • 7.4.3.14.1. HIV market, 2018 - 2030 (USD Million)
    • 7.4.3.15. Hepatitis C
      • 7.4.3.15.1. Hepatitis C market, 2018 - 2030 (USD Million)
    • 7.4.3.16. Hepatitis B
      • 7.4.3.16.1. Hepatitis B market, 2018 - 2030 (USD Million)
    • 7.4.3.17. Other infectious diseases
      • 7.4.3.17.1. Other infectious diseases market, 2018 - 2030 (USD Million)
  • 7.4.4. Genetic testing
    • 7.4.4.1. Genetic testing market, 2018 - 2030 (USD Million)
    • 7.4.4.2. Newborn screening
      • 7.4.4.2.1. Newborn screening market, 2018 - 2030 (USD Million)
    • 7.4.4.3. Predictive and presymptomatic testing
      • 7.4.4.3.1. Predictive and presymptomatic testing market, 2018 - 2030 (USD Million)
    • 7.4.4.4. Others
      • 7.4.4.4.1. Others market, 2018 - 2030 (USD Million)
  • 7.4.5. Neurological disease
    • 7.4.5.1. Neurological disease market, 2018 - 2030 (USD Million)
  • 7.4.6. Cardiovascular disease
    • 7.4.6.1. Cardiovascular disease market, 2018 - 2030 (USD Million)
  • 7.4.7. Microbiology
    • 7.4.7.1. Microbiology market, 2018 - 2030 (USD Million)
  • 7.4.8. Others
    • 7.4.8.1. Others market, 2018 - 2030 (USD Million)

Chapter 8. Molecular Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.4. Spain
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.6. Belgium
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Belgium market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.7. Switzerland
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Switzerland market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.8. Netherlands
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Netherlands market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.9. Poland
    • 8.4.9.1. Key country dynamics
    • 8.4.9.2. Regulatory framework/ reimbursement structure
    • 8.4.9.3. Competitive scenario
    • 8.4.9.4. Poland market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.10. Austria
    • 8.4.10.1. Key country dynamics
    • 8.4.10.2. Regulatory framework/ reimbursement structure
    • 8.4.10.3. Competitive scenario
    • 8.4.10.4. Austria market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.11. Denmark
    • 8.4.11.1. Key country dynamics
    • 8.4.11.2. Regulatory framework/ reimbursement structure
    • 8.4.11.3. Competitive scenario
    • 8.4.11.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.12. Sweden
    • 8.4.12.1. Key country dynamics
    • 8.4.12.2. Regulatory framework/ reimbursement structure
    • 8.4.12.3. Competitive scenario
    • 8.4.12.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.13. Turkey
    • 8.4.13.1. Key country dynamics
    • 8.4.13.2. Regulatory framework/ reimbursement structure
    • 8.4.13.3. Competitive scenario
    • 8.4.13.4. Turkey market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.14. Norway
    • 8.4.14.1. Key country dynamics
    • 8.4.14.2. Regulatory framework/ reimbursement structure
    • 8.4.14.3. Competitive scenario
    • 8.4.14.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. China
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.5. Thailand
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.6. Sri Lanka
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Sri Lanka market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.7. Malaysia
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Malaysia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.8. Vietnam
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework/ reimbursement structure
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Vietnam market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.9. Singapore
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Regulatory framework/ reimbursement structure
    • 8.5.9.3. Competitive scenario
    • 8.5.9.4. Singapore market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.2. Colombia
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Colombia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.3. Chile
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Chile market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.4. Peru
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Peru market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.5. Argentina
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.3. Jordan
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. Jordan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.5. Qatar
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Qatar market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.6. Egypt
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Egypt market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.7. Kuwait
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework/ reimbursement structure
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Recent Developments & Impact Analysis by Key Market Participants
• 9.3. Company Market Share Analysis, 2024
• 9.4. Key Company Profiles
  • 9.4.1. BD
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. BIOMERIEUX
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Bio-Rad Laboratories, Inc.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Abbott
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Agilent Technologies, Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Danaher
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Hologic Inc. (Gen Probe)
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Illumina, Inc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Grifols
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. QIAGEN
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. F. Hoffmann-La Roche, Ltd.
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. Siemens Healthineers AG
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives
  • 9.4.13. Sysmex Corporatio

관련자료